3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
33
Thyroid Neoplasms
9
Neoplasms
8
Thyroid Carcinoma, Anaplastic
7
Thyroid Cancer, Papillary
4
Neoplasm Metastasis
4
Multiple Myeloma
4
Colorectal Neoplasms
4
Ameloblastoma
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Skin Neoplasms
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Adenocarcinoma, Follicular
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Thrombocytosis
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Sexual Dysfunction, Physiological
1
Rare Malignant Neoplasm
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
dabrafenib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled